These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 11414684)
1. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Schrag ML; Wienkers LC Arch Biochem Biophys; 2001 Jul; 391(1):49-55. PubMed ID: 11414684 [TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Patki KC; Von Moltke LL; Greenblatt DJ Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972 [TBL] [Abstract][Full Text] [Related]
3. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383 [TBL] [Abstract][Full Text] [Related]
4. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Schrag ML; Wienkers LC Drug Metab Dispos; 2001 Jan; 29(1):70-5. PubMed ID: 11124232 [TBL] [Abstract][Full Text] [Related]
5. Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Nakamura H; Nakasa H; Ishii I; Ariyoshi N; Igarashi T; Ohmori S; Kitada M Drug Metab Dispos; 2002 May; 30(5):534-40. PubMed ID: 11950784 [TBL] [Abstract][Full Text] [Related]
6. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Shou M; Mei Q; Ettore MW; Dai R; Baillie TA; Rushmore TH Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):845-53. PubMed ID: 10359672 [TBL] [Abstract][Full Text] [Related]
8. Structure-function analysis of human CYP3A4 using a specific proinhibitory antipeptide antibody. Schulz-Utermoehl T; Mountfield RJ; Bywater RP; Madsen K; Jørgensen PN; Hansen KT Drug Metab Dispos; 2000 Jul; 28(7):718-25. PubMed ID: 10859142 [TBL] [Abstract][Full Text] [Related]
9. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984 [TBL] [Abstract][Full Text] [Related]
11. Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). Schrag ML; Wienkers LC Drug Metab Dispos; 2000 Oct; 28(10):1198-201. PubMed ID: 10997940 [TBL] [Abstract][Full Text] [Related]
12. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Schrag ML; Wienkers LC Adv Exp Med Biol; 2001; 500():347-50. PubMed ID: 11764967 [No Abstract] [Full Text] [Related]
13. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Wang RW; Newton DJ; Scheri TD; Lu AY Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550 [TBL] [Abstract][Full Text] [Related]
14. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Khan KK; He YQ; Domanski TL; Halpert JR Mol Pharmacol; 2002 Mar; 61(3):495-506. PubMed ID: 11854429 [TBL] [Abstract][Full Text] [Related]
15. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Brandes LJ; Queen GM; LaBella FS Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318 [TBL] [Abstract][Full Text] [Related]
16. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211 [TBL] [Abstract][Full Text] [Related]
17. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Kanamitsu S; Ito K; Green CE; Tyson CA; Shimada N; Sugiyama Y Pharm Res; 2000 Apr; 17(4):419-26. PubMed ID: 10870985 [TBL] [Abstract][Full Text] [Related]
18. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation. Emoto C; Iwasaki K Xenobiotica; 2007 Jun; 37(6):592-603. PubMed ID: 17614006 [TBL] [Abstract][Full Text] [Related]